No Data
No Data
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Zhixiang Jintai (688443.SH) released its performance for the first half of the year, with a net loss of 0.362 billion yuan.
Zhixiang Jintai (688443.SH) released the 2024 interim report, with a revenue of 1...
Genrix Biopharmaceutical's Celecoxib Injection Gets Nod to Be Registered; Shares Drop 4%
The first approved product on the market, Zhixiang Jintai (688443.SH): Celgene's monoclonal antibody for the treatment of moderate to severe plaque psoriasis.
Zhixiang Jintai (688443.SH) announced today that the company has received the "Pharmaceuticals..." issued by the State Administration for Market Regulation.
Chongqing Genrix Biopharmaceutical (SHSE:688443) Is Using Debt Safely
No Data